PHIBRO ANIMAL HEALTH CORP (PAHC)
Health Care / Pharmaceuticals
S&P SmallCap 600$33.29
Scores poorly across most models. Proceed with caution.
Avoid
Score based on 4 of 5 models — moderate confidence
Is PHIBRO ANIMAL HEALTH CORP a Good Investment in 2026?
PHIBRO ANIMAL HEALTH CORP (PAHC) scores 2.5 out of 10 on AlphaStocks' composite model, earning a Avoid rating. The Piotroski model rates PHIBRO ANIMAL HEALTH CORP as Attractive (6/9). However, the Lynch model rates it Caution. PHIBRO ANIMAL HEALTH CORP currently trades above its estimated fair value of $26, suggesting limited upside at current prices. PHIBRO ANIMAL HEALTH CORP ranks #1067 out of 1121 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Estimated Fair Value
Trading slightly above estimated fair value.
Model-based estimate, not a price target.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Attractive
6/9
Buffett
Caution
Business quality & competitive moat
Graham
Neutral
Significantly above fair value
Lynch
Caution
Growth rate vs price (PEG)
Greenblatt
Neutral
Bottom half (rank 71%)
Frequently Asked Questions
Is PHIBRO ANIMAL HEALTH CORP (PAHC) a good investment?
What is PHIBRO ANIMAL HEALTH CORP's Piotroski F-Score?
Is PAHC overvalued or undervalued?
How does PAHC compare to other Health Care stocks?
What do investment models say about PAHC?
Similar Stocks
Compare PAHC with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer